Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

The pharmacogenomics journal - 1 Jan 2002

Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming G F, Vokes E E, Schilsky R L, Ratain M J

Abstract excerpt

The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically inactive SN-38 glucuronide (SN-38G). We have previously demonstrated the role of UGT1A1 enzyme in the glucuronidation of SN-38 and a significant correlation between in vitro glucuronidation of SN-38 and UGT1A1 gene promoter polymorphism. This polymorphism (UGT1A1*28) is characterized by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Genotype

Share to Glucuronides

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 11990381
DOI: 10.1038/sj.tpj.6500072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.PMID 11990381Read ↗

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.Semantic proximity Read ↗

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.Semantic proximity Read ↗

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.Semantic proximity Read ↗

The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.Semantic proximity Read ↗

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.Semantic proximity Read ↗

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.Semantic proximity Read ↗

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.